

Abilify Maintena® (aripiprazole) - New indication

- On July 28, 2017, Otsuka announced the FDA approval of Abilify Maintena (aripiprazole) extendedrelease injectable suspension, for maintenance monotherapy treatment of bipolar I disorder in adults.
 - Previously, Abilify Maintena was only approved for the treatment of schizophrenia.
- The new approval of Abilify Maintena was established in a placebo-controlled trial in adults with bipolar I disorder. The primary efficacy endpoint was time from randomization to recurrence of any mood episode.
 - Abilify Maintena demonstrated a significantly longer time to recurrence of any mood episodes vs. placebo, including both manic and mixed mood episodes.
 - However, here was no substantial difference between treatment groups in delaying time to recurrence of depressive mood episodes.
- Abilify Maintena carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis.
- For both bipolar I disorder and schizophrenia, the recommended starting and maintenance dose of Abilify Maintena is 400 mg intramuscularly once monthly (no sooner than 26 days after the previous injection).
 - Tolerability should be established in patients who have never taken aripiprazole with oral aripiprazole prior to initiating treatment with Abilify Maintena. Due to the half-life of oral aripiprazole, it may take up to 2 weeks to fully assess tolerability.
 - After the first dose of Abilify Maintena, administer oral aripiprazole (10 mg or 20 mg) for 14 consecutive days to achieve therapeutic aripiprazole concentrations during initiation of therapy.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.